SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-23-130398
Filing Date
2023-05-01
Accepted
2023-05-01 16:07:58
Documents
8
Period of Report
2023-06-15

Document Format Files

Seq Description Document Type Size
1 DEF 14A d456303ddef14a.htm DEF 14A 689712
2 GRAPHIC g456303g02m00.jpg GRAPHIC 40221
3 GRAPHIC g456303g16m01.jpg GRAPHIC 20032
4 GRAPHIC g456303g16m02.jpg GRAPHIC 47281
5 GRAPHIC g456303g16m03.jpg GRAPHIC 44875
6 GRAPHIC g456303g34m01.jpg GRAPHIC 63911
7 GRAPHIC g456303g34m02.jpg GRAPHIC 66281
8 GRAPHIC g456303g81u29.jpg GRAPHIC 4372
  Complete submission text file 0001193125-23-130398.txt   1080445
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

IRS No.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-35890 | Film No.: 23873642
SIC: 2834 Pharmaceutical Preparations